Medincell's partner teva announces recruitment completion of phase 3 clinical study of mdc-tjk / olanzapine long-acting injectable (lai)

Montpellier, france--(business wire)--teva pharmaceutical industries ltd. announced the successful completion of the enrollment in the eu and us of the anticipated 640 participants of the ongoing phase 3 clinical trial of mdc-tjk (tev-44749) at the j.p. morgan healthcare conference. results of the study are expected in the second half of 2024.1 mdc-tjk is an investigational once-monthly subcutaneous long-acting injection of the atypical antipsychotic olanzapine for the treatment of schizophreni.
TEVA Ratings Summary
TEVA Quant Ranking